These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6733845)

  • 1. Calcium modifies the accumulation and retention of daunorubicin by Ehrlich ascites carcinoma.
    Murray SL; Du Vall EM; Slater LM
    Cancer Chemother Pharmacol; 1984; 13(1):69-70. PubMed ID: 6733845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
    Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
    Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells.
    Friche E; Skovsgaard T; Nissen NI
    Cancer Chemother Pharmacol; 1987; 19(1):35-9. PubMed ID: 3815723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
    [No Abstract]   [Full Text] [Related]  

  • 6. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.
    Slater LM; Murray SL; Wetzel MW; Wisdom RM; DuVall EM
    J Clin Invest; 1982 Nov; 70(5):1131-4. PubMed ID: 6182160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
    Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
    Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
    Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1978; 27(8):1221-7. PubMed ID: 567991
    [No Abstract]   [Full Text] [Related]  

  • 11. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.
    Dano K
    Biochim Biophys Acta; 1973 Oct; 323(3):466-83. PubMed ID: 4796512
    [No Abstract]   [Full Text] [Related]  

  • 12. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcellular localization of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells.
    Londos-Gagliardi D; Aubel-Sadron G; Maral R; Trouet A
    Eur J Cancer (1965); 1980 Jun; 16(6):849-54. PubMed ID: 7408932
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129.
    Meador J; Sweet P; Stupecky M; Wetzel M; Murray S; Gupta S; Slater L
    Cancer Res; 1987 Dec; 47(23):6216-9. PubMed ID: 3677073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.
    Londos-Gagliardi D; Baurain R; Robert J; Aubel-Sadron G
    Cancer Chemother Pharmacol; 1982; 9(1):45-8. PubMed ID: 6958392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Res; 1980 Apr; 40(4):1077-83. PubMed ID: 7357538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines.
    Litman T; Nielsen D; Skovsgaard T; Zeuthen T; Stein WD
    Biochim Biophys Acta; 1997 Aug; 1361(2):147-58. PubMed ID: 9300796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.
    Sehested M; Skovsgaard T; Roed H
    Biochem Pharmacol; 1988 Sep; 37(17):3305-10. PubMed ID: 3401258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.